Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents
Blood Reviews
Available online 21 April 2020, 100694
Abstract
Platelets
are central to inflammation-related manifestations of cardiovascular
diseases (CVD) such as atherosclerosis. Platelet-activating factor
(PAF), thrombin, thromboxane A2 (TxA2), and
adenosine diphosphate (ADP) are some of the key agonists of platelet
activation that are at the intersection between a plethora of
inflammatory pathways that modulate pro-inflammatory and coagulation
processes. The aim of this article is to review the role of platelets
and the relationship between their structure, function, and the
interactions of their constituents in systemic inflammation and
atherosclerosis. Antiplatelet therapies are discussed with a view to
primary prevention of CVD by the clinical reduction of platelet
reactivity and inflammation. Current antiplatelet therapies are
effective in reducing cardiovascular risk but increase bleeding risk.
Novel therapeutic antiplatelet approaches beyond current pharmacological
modalities that do not increase the risk of bleeding require further
investigation. There is potential for specifically designed
nutraceuticals that may become safer alternatives to pharmacological
antiplatelet agents for the primary prevention of CVD but there is
serious concern over their efficacy and regulation, which requires
considerably more research.

No comments:
Post a Comment